BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Black CM, Yu E, McCann E, Kachroo S. Dose Escalation and Healthcare Resource Use among Ulcerative Colitis Patients Treated with Adalimumab in English Hospitals: An Analysis of Real-World Data. PLoS One 2016;11:e0149692. [PMID: 26919745 DOI: 10.1371/journal.pone.0149692] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Gemayel NC, Rizzello E, Atanasov P, Wirth D, Borsi A. Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence. Current Medical Research and Opinion 2019;35:1911-23. [DOI: 10.1080/03007995.2019.1631058] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
2 Guberna L, Nyssen OP, Chaparro M, Gisbert JP. Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. J Clin Med 2021;10:2132. [PMID: 34069295 DOI: 10.3390/jcm10102132] [Reference Citation Analysis]
3 Taxonera C, Iglesias E, Muñoz F, Calvo M, Barreiro-de Acosta M, Busquets D, Calvet X, Rodríguez A, Pajares R, Gisbert JP, López-Serrano P, Pérez-Calle JL, Ponferrada Á, De la Coba C, Bermejo F, Chaparro M, Olivares D, Alba C, Fernández-Blanco I. Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation. Dig Dis Sci 2017;62:481-90. [PMID: 27995400 DOI: 10.1007/s10620-016-4398-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
4 Pöllinger B, Schmidt W, Seiffert A, Imhoff H, Emmert M. Costs of dose escalation among ulcerative colitis patients treated with adalimumab in Germany. Eur J Health Econ 2019;20:195-203. [PMID: 29362899 DOI: 10.1007/s10198-017-0953-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Tomkins S, Chapman C, Myland M, Tham R, de Nobrega R, Jackson B, Keshav S. Treating iron deficiency in patients with gastrointestinal disease: Risk of re-attendance in secondary care. PLoS One 2017;12:e0189952. [PMID: 29244881 DOI: 10.1371/journal.pone.0189952] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 Hoque S, Puenpatom A, Boccaletti S, Green C, Black CM, Roberts J, Rajkovic I, Milligan G. Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience. BMJ Open Gastroenterol 2020;7:e000476. [PMID: 33199269 DOI: 10.1136/bmjgast-2020-000476] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Danese S, Fiorino G, Peyrin-Biroulet L. Early intervention in Crohn's disease: towards disease modification trials. Gut 2017;66:2179-87. [PMID: 28874419 DOI: 10.1136/gutjnl-2017-314519] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 12.0] [Reference Citation Analysis]
8 Vasudevan A, Gibson PR, Van Langenberg DR. Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2019;25:1462-73. [DOI: 10.1093/ibd/izy399] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
9 Dignass A, Waller J, Cappelleri JC, Modesto I, Kisser A, Dietz L, DiBonaventura M, Wood R, May M, Libutzki B, Bargo D. Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs. J Med Econ 2020;23:415-27. [PMID: 31858853 DOI: 10.1080/13696998.2019.1707210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Annese V, Nathwani R, Alkhatry M, Al-Rifai A, Al Awadhi S, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Taha MS, Limdi JK. Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates. Therap Adv Gastroenterol 2021;14:17562848211065329. [PMID: 34987611 DOI: 10.1177/17562848211065329] [Reference Citation Analysis]
11 Null KD, Xu Y, Pasquale MK, Su C, Marren A, Harnett J, Mardekian J, Manuchehri A, Healey P. Ulcerative Colitis Treatment Patterns and Cost of Care. Value Health. 2017;20:752-761. [PMID: 28577692 DOI: 10.1016/j.jval.2017.02.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
12 Samaan MA, Pavlidis P, Digby-Bell J, Johnston EL, Dhillon A, Paramsothy R, Akintimehin AO, Medcalf L, Chung-Faye G, DuBois P, Koumoutsos I, Powell N, Anderson SHC, Sanderson J, Hayee BH, Irving PM. Golimumab: early experience and medium-term outcomes from two UK tertiary IBD centres. Frontline Gastroenterol. 2018;9:221-231. [PMID: 30047549 DOI: 10.1136/flgastro-2017-100895] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
13 Kunovszki P, Judit Szántó K, Gimesi-országh J, Takács P, Borsi A, Bálint A, Farkas K, Milassin Á, Lakatos PL, Szamosi T, Molnár T. Epidemiological data and utilization patterns of anti-TNF alpha therapy in the Hungarian ulcerative colitis population between 2012-2016. Expert Opinion on Biological Therapy 2020;20:443-9. [DOI: 10.1080/14712598.2020.1718097] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]